Arama Sonuçları - Alain Baron
- Gösterilen 1 - 20 sonuçlar arası kayıtlar. 24
- Sonraki Sayfaya Git
-
1
Improving apple juice expression and quality by pulsed electric field on an industrial scale Yazar: Mohammad Turk, Eugène Vorobiev, Alain Baron
Baskı/Yayın Bilgisi 2012Artigo -
2
Insulin resistance in the vasculature Yazar: Kieren J. Mather, Helmut O. Steinberg, Alain Baron
Baskı/Yayın Bilgisi 2013Carta -
3
Endothelin Limits Insulin Action in Obese/Insulin-Resistant Humans Yazar: Amale Lteif, Prashant Vaishnava, Alain Baron, Kieren J. Mather
Baskı/Yayın Bilgisi 2007Artigo -
4
-
5
Antiobesity Effects of the β-Cell Hormone Amylin in Diet-Induced Obese Rats: Effects on Food Intake, Body Weight, Composition, Energy Expenditure, and Gene Expression Yazar: Jonathan D. Roth, Heather Hughes, Eric S. Kendall, Alain Baron, Christen M. Anderson
Baskı/Yayın Bilgisi 2006Artigo -
6
-
7
-
8
Composition and properties of the polyphenolic extracts obtained from industrial plum pomaces Yazar: Michał Sójka, Krzysztof Kołodziejczyk, Joanna Milala, Maribel Abadías, İnmaculada Viñas, Sylvain Guyot, Alain Baron
Baskı/Yayın Bilgisi 2014Artigo -
9
-
10
-
11
-
12
Polycystic Ovary Syndrome Is Associated With Endothelial Dysfunction Yazar: Giancarlo Paradisi, Helmut O. Steinberg, Annette Hempfling, Jessica Cronin, Ginger Hook, Marguerite K. Shepard, Alain Baron
Baskı/Yayın Bilgisi 2001Artigo -
13
-
14
Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure Yazar: Que Liu, Christen M. Anderson, Anatoly Broyde, Clara J. Polizzi, Rayne Fernandez, Alain Baron, David G. Parkes
Baskı/Yayın Bilgisi 2010Artigo -
15
Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials Yazar: Ralph A. DeFronzo, John B. Buse, Terri Kim, Colleen Burns, Sharon Skare, Alain Baron, Mark Fineman
Baskı/Yayın Bilgisi 2016Artigo -
16
Effect on Glycemic Control of Exenatide (Synthetic Exendin-4) Additive to Existing Metformin and/or Sulfonylurea Treatment in Patients With Type 2 Diabetes Yazar: Mark Fineman, Thomas A. Bicsak, Larry Z. Shen, Kristin Taylor, Eling Gaines, Amanda Varns, Dennis Kim, Alain Baron
Baskı/Yayın Bilgisi 2003Artigo -
17
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea Yazar: David M. Kendall, Matthew C. Riddle, Julio Rosenstock, Dongliang Zhuang, Dennis Dong Hwan Kim, Mark Fineman, Alain Baron
Baskı/Yayın Bilgisi 2005Artigo -
18
The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies Yazar: John B. Buse, Ralph A. DeFronzo, Julio Rosenstock, Terri Kim, Colleen Burns, Sharon Skare, Alain Baron, Mark Fineman
Baskı/Yayın Bilgisi 2015Artigo -
19
-
20
Arama Araçları:
İlgili Konular
Endocrinology
Internal medicine
Medicine
Diabetes mellitus
Insulin
Type 2 diabetes
Insulin resistance
Exenatide
Alternative medicine
Pathology
Placebo
Gastroenterology
Biology
Obesity
Receptor
Vasodilation
Blood pressure
Endothelial dysfunction
Glycemic
Islet
Metformin
Postprandial
Adverse effect
Amylin
Biochemistry
Chemistry
Endothelin receptor
Endothelium
Gastric emptying
Pharmacology